title: Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
abstract: Combined chelation treatment may be a better approach for transfusion-dependent thalassemia major patients with iron overload complications because of increased efficacy. Combination therapy with desferrioxamine and deferiprone has already been reported to improve survival dramatically by reversing cardiac dysfunction and other endocrine complications. Some patients have intolerance or inconvenience to parenteral desferrioxamine. The hypothesis of this study was that combining two oral chelators, deferiprone and deferasirox, might lead to similar results. Following approval by the hospital ethical committee and a written informed consent from each patient, 16 patients who fulfilled the criteria participated in a study protocol for a period of up to 2 years. Efficacy measures analysis demonstrated a statistically significant decrease of total body iron load as estimated by serum ferritin, LIC and MRI T2* indices. Regarding the safety assessment, the incidence of adverse events was minor compared to the associated toxicity of monotherapy of each drug. No new onset of iron overload-related complications was demonstrated. A reversal of cardiac dysfunction was observed in 2/4 patients, while the mean LVEF increased significantly. Regarding endocrine assessment, in 2/8 patients with impaired glucose tolerance, we noted a significant decrease in the mean 2h glucose in OGTT. Additionally an improvement in gonadal function was observed and one male and one female gave birth to two healthy children without hormonal stimulation. Combined oral chelation in thalassemia offers the promise of easier administration, better compliance and may lead to an improvement of patient quality of life by preventing or even reversing iron overload complications.
authors.affiliation: Thalassemia Unit, General Hospital of Corinth, 1 Dervenakion, Corinth, Greece. kallistheni.farmaki@gmail.com
authors.forename: Kallistheni
authors.initials: K
authors.lastname: Farmaki
authors.forename: Ioanna
authors.initials: I
authors.lastname: Tzoumari
authors.forename: Christina
authors.initials: C
authors.lastname: Pappa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D006066:Gonads / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006334:Heart Function Tests; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D013961:Thyroid Gland / Q000187:drug effects; D065227:Transfusion Reaction; D055815:Young Adult; D017086:beta-Thalassemia / Q000150:complications* / Q000188:drug therapy / Q000628:therapy*
chemical_list: D001786:Blood Glucose; D007502:Iron Chelating Agents; D007501:Iron